Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

The high-stakes push to get COVID vaccines to young children

The Omicron variant and and anti-vaccine backlash are complicating the effort.

Axios

Sadiq Khan calls on leading vaccine manufacturers to share Covid jab blueprints with world

Exclusive: Sadiq Khan, alongside mayors of New York and Johannesburg, urged companies ‘to do all you can’ to promote vaccine equity and ‘help stop the unnecessary loss of life’

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna co-founder joins board of surgical robot startup

A big name in the medical field is joining the board of Galen Robotics, a biotech startup in Baltimore.

Tribune News Service

No Evidence to Support Widespread Use of Fourth COVID Shot, Say EU Agencies

EU health agencies said on Wednesday there was no evidence to support the use of a fourth dose of COVID-19 vaccines developed by Pfizer and Moderna in the general population, but they recommend a second booster for people aged 80 and above. There is no clear evidence in the European…

Asharq Al-Awsat

Future of COVID boosters comes down to crucial meeting of FDA Advisers

An all-star panel of COVID-19 experts will convene this week to hash out how and when vaccines should be updated to address future variants as the virus continues to rapidly mutate.

Tribune News Service

See Why COVAX, African Union Refuse To Buy More Moderna's COVID-19 Vaccine

COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine despite the low immunization rate as developing nations struggle to allocate supplies. The African Union and Covax decided not to obtain more of the vaccine as developing nations struggle…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

COVAX, African Union Decline to Buy More Doses of Moderna’s COVID Shots

COVAX, the global project to share COVID-19 vaccines, and the African Union have declined options to buy additional doses of Moderna's shot, as developing nations struggle to allocate supplies. A spokesperson for Gavi, part of the COVAX alliance, confirmed the news. The discussions with Moderna are part of "regular decision-making…

Asharq Al-Awsat

One of world’s first Omicron Covid-19 variant vaccines to be trialled in Greater Manchester

Volunteers are being asked to step forward to take part in the study

Manchester Evening News

mRNA Vaccine Maker CEOs Pocketed $100M In Pandemic Pay: FT

The CEOs of Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) have sha

Benzinga

What Are Whales Doing With Moderna

Benzinga

COVID-19 vaccines for the youngest children may be inching closer to authorization – a pediatrician explains how they're being tested

For some parents of young children, the wait for COVID-19 vaccines has been long and agonizing.

The Conversation

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

Here's Why Moderna Shares Are Rising

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 4.67% at $181.16 after the company received FDA approval for Emergency Use Authorization for a second booster dose of its COVID-19 vaccine.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ:

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Chicago Sun-Times

FDA approves another COVID booster for 50 and up

The Food and Drug Administration’s decision opens a fourth dose of the Pfizer or Moderna vaccines to those people at least four months after their previous booster.

The Independent UK

FDA approves another Pfizer, Moderna Covid booster for 50 and up

US regulators are allowing people 50 and older to get another booster dose of the Pfizer or Moderna Covid-19 vaccine

Get all your
news in one place.

100’s of premium titles.
One news app.

The Times of India

World moves from shortages to possible glut of Covid-19 vaccines

NEW YORK: After racing to build capacity and meet once seemingly insatiable orders for Covid-19 shots, the global vaccine industry is facing waning demand as many late-to-market producers fight over a slowing market.

Benzinga

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Tribune News Service

COVID-19 boosters, BA.2 subvariant, treatments: 6 things we still need to keep an eye on

Coronavirus case numbers have plummeted across much of the U.S., including Texas, a promising sign that COVID-19 could finally be waning. But the pandemic is far from over, especially for older adults, people with disabilities and other vulnerable populations.

The Independent UK

Covid vaccinations in US fall to lowest level since 2020

Public health experts say the low number of Americans receiving booster shots is an ‘unforgivable liability’

Benzinga

What 10 Analyst Ratings Have To Say About Moderna

Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings:

The Independent UK

FDA advisory panel to discuss Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

Benzinga

This Is What Whales Are Betting On Moderna

1 … 27 28 29 30

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.